Literature DB >> 32716108

TRIM31 inhibits NLRP3 inflammasome and pyroptosis of retinal pigment epithelial cells through ubiquitination of NLRP3.

Peirong Huang1,2,3, Wenjia Liu1,2,3, Jieqiong Chen1,2, Yifan Hu1,2,3, Yuwei Wang1,2,3, Junran Sun1,2,3, Jingyang Feng1,2,3.   

Abstract

NOD-like receptor protein 3 (NLRP3) is associated with age-related macular degeneration (AMD). Retinal pigment epithelial (RPE) cells serve as the immune defense of macula, and their dysfunction causes clinically relevant changes in AMD. In the present study, oxidized low-density lipoprotein (ox-LDL) activated the NLRP3 inflammasome in human RPE cell line ARPE-19. Our data showed that the expression of NLRP3, interleukin-1β (IL-1β), and caspase-1 and the release of IL-1β in ARPE-19 cells were substantially increased by ox-LDL, whereas the addition of NLRP3 inhibitor INF39 dose-dependently reversed the effect of ox-LDL. Overexpression of tripartite motif-containing protein 31 (TRIM31) also suppressed the effect of ox-LDL in ARPE-19 cells. TRIM31 knockdown had similar effects with ox-LDL but INF39 could block the effect of TRIM31 knockdown. Moreover, TRIM31 could interact with NLRP3 in ARPE-19 cells. Overexpression of TRIM31 increased NLRP3 ubiquitination. In conclusion, the results propose that TRIM31 could enhance NLRP3 ubiquitination, therefore inhibiting NLRP3 inflammasome and pyroptosis in human RPE cells.
© 2020 International Federation for Cell Biology.

Entities:  

Keywords:  NLRP3; TRIM31; retinal pigment epithelial cells

Mesh:

Substances:

Year:  2020        PMID: 32716108     DOI: 10.1002/cbin.11429

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  6 in total

Review 1.  Spotlight on pyroptosis: role in pathogenesis and therapeutic potential of ocular diseases.

Authors:  Meini Chen; Rong Rong; Xiaobo Xia
Journal:  J Neuroinflammation       Date:  2022-07-14       Impact factor: 9.587

Review 2.  Pyroptosis: A New Insight Into Eye Disease Therapy.

Authors:  Yun Zhang; Yan Jiao; Xun Li; Sheng Gao; Nenghua Zhou; Jianan Duan; Meixia Zhang
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

3.  The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes.

Authors:  Minxuan Xu; Jun Tan; Wei Dong; Benkui Zou; Xuepeng Teng; Liancai Zhu; Chenxu Ge; Xianling Dai; Qin Kuang; Shaoyu Zhong; Lili Lai; Chao Yi; Tingting Tang; Junjie Zhao; Longyan Wang; Jin Liu; Hao Wei; Yan Sun; Qiufeng Yang; Qiang Li; Deshuai Lou; Linfeng Hu; Xi Liu; Gang Kuang; Jing Luo; Mingxin Xiong; Jing Feng; Chufeng Zhang; Bochu Wang
Journal:  Nat Commun       Date:  2022-02-25       Impact factor: 14.919

4.  Downregulation of Inflammatory Response via Nrf2/Trx1/TXNIP Axis in Oxidative Stress-Induced ARPE-19 Cells and Mouse Model of AMD.

Authors:  Qian Yang; Wenting Cai; Huizi Jin; Tianyi Shen; Jing Yu
Journal:  Oxid Med Cell Longev       Date:  2022-08-12       Impact factor: 7.310

Review 5.  Emerging Roles of MHC Class I Region-Encoded E3 Ubiquitin Ligases in Innate Immunity.

Authors:  Xiuzhi Jia; Chunyuan Zhao; Wei Zhao
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

Review 6.  Novel Programmed Cell Death as Therapeutic Targets in Age-Related Macular Degeneration?

Authors:  Ming Yang; Kwok-Fai So; Wai Ching Lam; Amy Cheuk Yin Lo
Journal:  Int J Mol Sci       Date:  2020-10-01       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.